Element Science, a startup developing a wearable defibrillator for high-risk cardiovascular patients, raised $145.6 million in Series C funding from investors including GV, formerly Google Ventures.
The company will use the funding to support clinical studies and the commercial launch of the Jewel Patch Wearable Cardioverter Defibrillator. The wearable device is designed to both identify and treat life-threatening arrhythmias in patients at risk of sudden cardiac death. The funding will also help Element Science develop more digital wearables that will use the Jewel platform to monitor and treat cardiovascular conditions.
"Our next-generation digital wearable is a unique breakthrough in personalized digital healthcare based on years of extensive research and testing. The Jewel platform supports both therapeutic and diagnostic capabilities and is designed for ease of wearability to facilitate high compliance and efficacy," Uday Kumar, MD, the founder, president and CEO of the startup, said in a March 3 news release.
Dr. Kumar is a cardiac electrophysiologist, founder of iRhythm Technologies and a faculty member at Stanford (Calif.) University's Byers Center for Biodesign. Other leaders of the startup include a scientific advisory board with members representing Stanford University's department of medicine, Yale New Haven (Conn.) Hospital and the Cardiac Arrhythmia Service at Boston-based Massachusetts General Hospital.
More articles on health IT:
HIMSS cancels 2020 conference due to coronavirus
Hartford HealthCare tech accelerator finds home in new innovation center
Lawmakers revisit Project Nightingale, demanding more info from Ascension, Google & 14 other health IT notes